An Open-label Trial to Evaluate the Absorption, Metabolism, and Excretion of a Single Dose of [14C]-Tavapadon in Healthy Adult Male Subjects at Steady State
Latest Information Update: 20 Nov 2020
At a glance
- Drugs Tavapadon (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Cerevel Therapeutics
- 16 Nov 2020 Status changed from active, no longer recruiting to completed.
- 05 Aug 2020 Planned End Date changed from 12 May 2020 to 8 Nov 2020.
- 05 Aug 2020 Planned primary completion date changed from 12 May 2020 to 8 Nov 2020.